High Dose Oestrogen in Life Threatening Obscure Gastrointestinal Bleeding
Abstract
Keywords
References
ASGE Standards of Practice Committee, Fisher L, Lee Krinsky M, et al. The role of endoscopy in the management of obscure GI bleeding. Gastrointest Endosc. 2010;72:471-9.
Harrison DF. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope. 1982;92:314-20.
Zuckerman GR, Prakash C, Askin MP, et al. AGA technical review: evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterol. 2000;118:201-21.
Bronner MH, Pate MB, Cunningham JT, et al. Estrogenprogesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial. Ann Intern Med. 1986;105:371–4.
Van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet. 1990;335:953–5.
Van Cutsem E, Rutgeerts P, Coremans G, et al. Dose-response study of hormonal therapy in bleeding gastrointestinal vascular malformations (abstr). Gastroenterology. 1993;104:A286.
Barkin JS, Ross BS. Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol. 1998;93:1250-4.
Lewis B, Salomon P, Rivera-MacMurray S, et al. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol. 1992;15:99–103.
Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterol. 2001;121:1073-9.
Apostolopoulos P, Liatsos C, Gralnek IM, et al. Evaluation of capsule endoscopy in active, mild-to-moderate, overt, obscure GI bleeding. Gastrointest Endosc. 2007;66:1174-81.
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution 4.0 International License.